SinoPharm: December moina te coronavirus vaccine olabo

August 19, 2020.  COVID-19 vaccine candidate Chinese pharmaceutical company para bona toh etu saal December moina te market te baboli koishe. Aro etu tuita(2) tawai laga dham toh 1,000 yuan (Rs 10,000) nahoile ($144) hobo. Tangor state para sai thaka Chinese pharmaceutical company SinoPharm laga chairman Liu Jingzhen para koishe ke, phase III clinical trials beche market te tawai toh paa soruh hobo. Tai para aro koishe ke, tangor cities laga students aro kam kura manuh khan vaccine toh loboli lage, hoilebi chaka chotu te manuh komti thaka nemite te nalaki koishe.  “desh te 1.4 million manuh thaka khan sob loboli nalaki” koikena tai para Tuesday din interview samay Guangming Daily te janai thishe. Liu koishe ke, SiniPharm, kuan para tuita(2) vaccines trials kuriase, ek saal te 220 million tawai olaboli parehbo., “ami nejor be vaccine tuita(2) loikena eku side effects thaka nai, koikena Liu Jingzhen para janai thishe. “market te vaccine ahile toh, tai laga dham besi nahobo, tawai toh 700 yuan nehina hobo. Tuita(2) tawai toh loile 1,000 yuan (nahoile $144) hobo,” tai koishe. “judi ekta tawai loile, protection toh 97% thibo aro antibodies toh asti para othibo,” chairman para koishe. “COVID-19 laga level bongch- boli toh atha moina neshina lakibo. Aro tuita(2) tawai loile, 100% protection thibo”, koikena  Russian news agency TASS para Liu Jingzhen laga kotha janai thishe. Tai aro koishe ke, ekta aro tuita tawai majot te samay toh 28 din thakibo. Konuba cases te tuita tawai toh eke logot be loboli parehbo aro etu left aro right hath te loboli lage. Ek par te vaccine toh charta micrograms lobo lage”, koikena company laga officials para janai thishe. Sinopharm company para vaccine candidates Beijing aro Wuhan te olai thaka toh te be phase III clinical trials toh June moina te United Arab Emirates logot thishe koishe.